News bioMérieux

Equities

BIM

FR0013280286

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris Other stock markets 13:37:41 19/05/2026 BST			5-day change	1st Jan Change
72.45 ^EUR	+0.69%		-1.83%	-34.32%

05-07	The Rally Spreads
05-06	L'Institut Merieux: bought an extra 1% in Biomérieux, bringing its total stake in company to around 60%	RE

All News

Mentions Relevance

05-06	L'Institut Merieux: bought an extra 1% in Biomérieux, bringing its total stake in company to around 60%	RE
05-04	BioMerieux : AG 2026 - 2025 Parent company financial statements	PU
05-04	BioMerieux : AG 2026 - 2025 List of directors	PU
05-04	BioMerieux : AG 2026 - 2025 Consolidated financial statements	PU
05-04	BioMerieux : AG 2026 - Statutory auditors' report - 2025 Parent company annual financial statements	PU
05-04	BioMerieux : AG 2026 - Notice of General Meeting	PU
05-04	BioMerieux : AG 2026 - Concordance tables - Annual Report - Mgt Report - CSR	PU
05-04	BioMerieux : AG 2026 - Assurance report on sustainability and taxonomy information	PU
05-04	BioMerieux : AG 2026 - Board of directors' report on the text of the resolutions	PU
05-04	BioMerieux : AG 2026 - Statutory auditors' report - 2025 consolidated financial statements	PU
05-04	BioMerieux : AG 2026 - Special report on performance share grants and stock options	PU
04-28	BioMerieux : Q1 (bioMerieux First Quarter 2026 Business Review 23.04.2026 transcript)	PU
04-24	Deutsche Bank Downgrades bioMérieux to Hold, Cuts PT	MT
04-23	BioMerieux: Disappointing Q1 and lower guidance undermine investor confidence
04-23	BioMérieux S.A., Q1 2026 Sales/ Trading Statement Call, Apr 23, 2026
04-23	BioMérieux tumbles on lowered annual guidance
04-23	BioMerieux : BioMérieux – First-Quarter 2026 Business Review	PU
04-23	Biomerieux Q1 sales EUR 984 million	RE
04-23	BioMerieux : Q1 (PR bioMerieux Sales Q1 2026)	PU
04-23	BioMerieux : First-Quarter 2026 Business Review	PU
04-20	First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives and Reduce Health System Costs Across G7 Countries	PR
04-20	BioMérieux S.A.Announces Multi-Country Health Economic Analysis Assessing Impact of Deploying Fast Identification and Antimicrobial Susceptibility Testing Early in Care Pathway for Patients with Bloodstream Infections At High-Risk of Sepsis	CI
04-20	BioMerieux : First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives and Reduce Health System Costs Across G7 Countries	PU
04-13	RBC Capital Favors Diasorin Over bioMérieux
04-10	AlphaValue Urges Patience on bioMérieux, Maintains Buy Rating